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Adult bone marrow multipotential stromal cells (MSCs) hold great promise in regenerative medicine and tissue engineering.
However, due to their low numbers upon harvesting, MSCs need to be expanded in vitro without biasing future diﬀerentiation for
optimal utility. In this concept paper, we focus on the potential use of epidermal growth factor (EGF), prototypal growth factor for
enhancing the harvesting and/or diﬀerentiation of MSCs. Soluble EGF was shown to augment MSC proliferation while preserving
early progenitors within MSC population, and thus did not induce diﬀerentiation. However, tethered form of EGF was shown to
promote osteogenic diﬀerentiation. Soluble EGF was also shown to increase paracrine secretions including VEGF and HGF from
MSC. Thus, soluble EGF can be used not only to expand MSC in vitro, but also to enhance paracrine secretion through drug-
releasing MSC-encapsulated scaﬀolds in vivo. Tethered EGF can also be utilized to direct MSC towards osteogenic lineage both in
vitro and in vivo.
1. MultipotentialStromal Cells/Mesenchymal
Stem Cells (MSCs)
1.1. MSC Overviews. Adult bone marrow multipotential
stromal cells / mesenchymal stem cells (MSCs) are multipo-
tent cells with strong paracrine activities of various growth
factors [1–7]. These cells were originally isolated as colony
forming adherent ﬁbroblast-like cells or colony forming unit
ﬁbroblastic cells (CFU-Fs) from bone marrow suspension
[8], but it was subsequently realized that these cells carry
multipotency capable of diﬀerentiating into multiple cell
lineages including osteoblasts, chondrocytes, adipocytes,
smooth muscle cells, skeletal and cardiac myocytes, endothe-
lial cells, and neurons [3–6, 9, 10].
Initially MSC diﬀerentiation and direct incorporation
into local tissues undergoing wound healing and tissue
regenerations were regarded as a primary mechanism of
MSC action; however, the contribution of MSC diﬀeren-
tiation and direct incorporation into regenerating tissues
remains debated [11]. For example, some groups showed
t h a tM S C sw e r ed i ﬀerentiated and incorporated as myocar-
diocytes or vascular cells (endothelial cell and vascular
smooth muscle cells) in newly formed vessels in MSC-based
cardioplasty models in rat (isogenic and allogenic MSC
transplantation) and pig (allogenic transplantation) [11–
14]. Human MSCs from adult bone marrow were engrafted
and diﬀerentiated into cardiomyocytes within myocardium
of SCID mice [15]. In contrast, another group showed
that bone marrow-derived cells were not incorporated into
newly formed blood vessels in hindlimb ischemia in mice
allogenic bone marrow transplantation model [16]. Direct
incorporation and diﬀerentiation of transplanted MSC into
keratinocytes and vascular cells were also shown in mice der-
mal wound healing model (allogenic MSC transplantation)2 Journal of Biomedicine and Biotechnology
[17–19], whereas others showed that MSC diﬀerentiation of
transplanted MSCs into keratinocytes and vascular cells was
notobservedinmicedermalwoundhealingmodel(allogenic
MSC transplantation) and mice limb ischemia models
(isogenic MSC transplantation) [20, 21]. Furthermore, even
when there is an early incorporation noted into regenerating
tissue, these cells are largely gone by one month[15]. The
eﬃcacy of engraftment of transplanted MSC was varied,
suggesting the presence of other mechanisms of MSC-
mediated promotion of tissue regeneration [7, 11].
One such mechanism is paracrine secretion of growth
factors and cytokines. MSCs are known to have a strong
paracrine capability of various growth factors and cytokines
such as vascular endothelial growth factor (VEGF) or hep-
atocyte growth factor (HGF), which promote angiogenesis
and wound healing [7, 22–24]. Indeed, conditioned medium
of MSCs was also shown to promote angiogenesis or wound
healing in animal models, suggesting the crucial role of
MSC’s paracrine action in promotion of angiogenesis and
wound healing [21, 23, 25].
1.2. In Vitro Expansion of MSCs. A major thrust is to use
MSCs pharmacologically. Even if the physiological involve-
ment of MSCs is debatable, studies have shown injected
MSCs to home to wounded tissues [1, 2, 4, 5]. However,
the availability of suﬃc i e n tn u m b e ro fM S C st h a tr e t a i n
their multipotency and paracrine activity is prerequisite for
successful MSC-based therapeutics and tissue engineering.
MSCs are present only in low frequency in the bone marrow
(one in 105-106 bone marrow mononuclear cells, lower
frequency in aged hosts) [5, 26], thus, MSCs harvested
from the bone marrow for pharmacological uses need to be
expanded in vitro. T h e s ec e l l sa r ee x p a n d a b l ein vitro [3, 27]
and that is one of the desirable characteristics about MSCs.
Current in vitro expansion strategies generally rely on the
use of fetal bovine serum, but this practice not only carries
inherent disease risks [28] but also hampers standardization
that is critical to establishing a broad clinical adoption.
Another issue about current MSC expansion is the loss of
diﬀerentiation, proliferative, and therapeutic potentials of
MSCs through in vitro expansion process [29, 30]. Thus,
there is a strong motivation to identify factors that might
be used in serum-free formulations to expand MSC in vitro
without losing diﬀerentiation capacity and to preserve self-
renewal and therapeutic potentials of undiﬀerentiated MSCs
[31].
A recent report found that a combination of transform-
ing growth factor-β (TGF-β), platelet-derived growth factor
(PDGF), and basic ﬁbroblast growth factors (bFGF) could
replace serum component in cell culture medium to expand
human MSCs ex vivo without compromising diﬀerentiation
potentials, at least up to 5 passages [32]. Subsequently, serum
and animal component-free MSC culture media (STEMPRO
MSC SFM, from Invitrogen, Carlsbad, CA) (MesenCult-
ACFCultureKit,fromSTEMCELLTechnologies,Vancouver,
Canada) became available on the market. The manufacturers
claim that the culture media exert superior MSC prolifera-
tion potentials while maintaining diﬀerentiation potentials
and colony formation potentials, as supported by at least one
study [33]. Those chemically-deﬁned media should be safer
and thus better for clinical settings, although the proprietary
composition of these culture media may hinder acceptance
in preclinical and clinical usage.
1.3. Heterogenous Populations within MSC Preparations.
Although MSCs possess vast proliferative potential, have
the capacity for self-renewal, and give rise to diﬀerentiated
progenies, all MSC populations analyzed by clonal assays
were shown to be heterogeneous, with individual cells capable
of various diﬀerentiation potential and expansion capacity
[34]. Thus, the International Society for Cellular Therapy
proposed MSCs to be named as multipotential mesenchymal
stromal cells, which can also be abbreviated as MSCs [35].
MSC populations in vitro are known to include early
progenitors or rapidly self-renewing (RS)-cells as well as
large slow replicating mature/senescent cells. It is early
progenitors or RS-cells which retain strong multipotentiality
for diﬀerentiation. In contrast, mature/senescent cells have
only limited diﬀerentiation potentials, and these cells pre-
dominate in multiple passaged MSCs [27, 29, 36].
One of the prominent characteristics about MSCs is
their ability to produce colonies after being seeded at low
density [8]. Generation of a single-cell derived colony relies
on the presence of early progenitors or RS cells in MSC
preparations. In other words, assessment of the colony
formation unit (CFU) can be used to gauge the proportion
of colony forming early progenitors in MSC population
[29, 37, 38]
The number of MSC within bone marrow mononuclear
cells was shown to decrease with age [26]. Moreover, both
MSCs from old donors and high passaged MSCs were
shown to have decreased paracrine activity and reduced
organ protective eﬀects upon transplantation [30, 39]. These
reports clearly suggest the importance of preserving early
progenitors or RS cells in MSC preparation to maintain
therapeutic potentials of MSCs.
1.4. MSC Expansion and Diﬀerentiation Potentials. To pre-
serveearlyprogenitorswithinMSCpopulations,self-renewal
of these cells has to be maintained or even enhanced through
invitroMSCexpansionprocess.Otherwise,earlyprogenitors
will be lost during in vitro expansion. Cell division is a
central step of self-renewal and expansion of these cells.
There are various growth factors and cytokines known to
w o r ka sam i t o g e n ,b u tt h ei d e a lg r o w t hf a c t o r sf o rin
vitro MSC expansion must reversibly suppress or at least
not alter the subsequent diﬀerentiation process. In other
words, these factors should not diminish diﬀerentiation
potentials of MSCs. Growth factors or cytokines which
promote diﬀerentiation of MSCs into certainlineages cannot
be used for in vitro MSC expansion, as the diﬀerentiation
process itself is antagonizing self-renewal of undiﬀerentiated
MSCs including early progenitors and the diﬀerentiation
would compromise utilization of these cells.
Among those growth factors, we have focused on epider-
mal growth factor (EGF) as a candidate to utilize in vitro
expansion of MSCs as EGF stimulates MSC proliferation
without altering diﬀerentiation process and potentials [3].Journal of Biomedicine and Biotechnology 3
2.EGFtoEnhanceSelf-Renewal and
Expansionof MSCs In Vitro
2.1.EGFandEGFReceptor. EGFwasoriginallyisolatedfrom
mouse salivary gland extract as a factor accelerating the
corneal wound healing [40], but it was soon recognized that
it is indeed a general growth factor exerting various actions
including cell migration and proliferation on a wide variety
of cells [41–43].
The EGF receptor (EGFR/ErbB-1 or human epidermal
growth factor receptor 1(HER1)) is the prototypal growth
factor receptor with intrinsic tyrosine kinase activity. It is
widely expressed on many cell types, including epithelial
and mesenchymal lineages [42]. Upon binding of at least
ﬁve genetically distinct ligands (including EGF, transforming
growth factor-α (TGF-α), and heparin-binding EGF (HB-
EGF)), the intrinsic tyrosine kinase within EGFR/ErbB-1 is
activated and phosphorylates the receptor itself (autophos-
phorylation) and numerous target downstream molecules.
Intracellular signaling pathways downstream of EGFR/ErbB-
1 include phosholipase Cγ (PLCγ) and its downstream
calcium- and protein kinase C (PKC)-mediated cascades,
ras activation leading to various mitogen activated protein
kinases (MAPK), other small GTPases such as rho and rac,
multiple signal transducer and activator of transcription
(STAT) isoforms, and heterotrimeric G proteins, phos-
phatidylinositol 3 -OH kinase (PI3K) and phospholipase D
(PLD) [3, 42, 43].
Upon ligand binding and activation, EGFR/ErbB-
1 undergoes internalization from the cell surface via
the clathrin-coated endocytic system. Within the acidic
late endosomal compartment, both EGF and EGF-bound
EGFR/ErbB-1 undergo degradation as EGF is a nondisso-
ciative ligand for EGF, whereas TGF-α-bound EGFR/ErbB-
1 is recycled back to cell surface after dissociation of TGF-
α from EGFR /ErbB-1 [42]. There is a growing evidence
suggesting that preferential and prolonged activation of
EGFR/ErbB-1 from cell surface exerts a distinct activity
from internalized EGFR/ErbB-1, as surface-tethered EGF
promotes cell spreading and survival of MSCs, whereas
soluble EGF does not (See discussion below) [44].
2.2. EGF Enhances MSC Proliferation. EGF is a prototypal
mitogen for various types of cells. Human MSCs express
EGFR/ErbB-1, and we and others demonstrated the mito-
genic eﬀect of EGF and HB-EGF on MSCs [3, 45]. Cell
proliferationisanintegralpartofself-renewalandexpansion
of the cells, and thus these data supports our hypothesis that
EGF can be used for in vitro MSC expansion, at least in
short-term culture setting; however, additive eﬀects of EGF
treatment on human MSC proliferation become less clear in
the long-term culture (Figure 1), presumably due to down-
regulation of EGFR/ErbB1, as discussed below.
The second aspect of expansion is to maintain colony-
forming units. In this aspect, EGF treatment is also success-
ful. EGF leads to a statistically signiﬁcant 25% increase in
stainable colonies (Figure 2), suggesting that EGF treatment
helps preserve early progenitors within human MSC popula-
tions.
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Figure 1: Eﬀect of EGF on primary human MSC proliferation
(a) and accumulative population doubling (PD)(b). (a) The cell
number of primary human MSCs increases about 5.5-fold in the
diluent (Ctrl) in culture medium supplemented with 17% FBS in
120 hours (5 days) time period. The addition of EGF (10nM) gives
an extra increase of cell counts to 8.5-fold. Total of 10000 cells was
seeded per each well in 12-well plate and the cell count of each
well was measured by Coulter Cell Counter Z2 (Beckman Coulter,
Inc. Fullerton, CA). Shown are mean ± s.e.m. of three experiments;
each performed in triplicate. The diﬀerences in proliferation were
compared between growth factor and diluent (Ctrl) exposed (∗P<
.05). (b) Accumulated PD of primary human MSCs in day 5 and
19 in the culture condition same as (a). After cell counting at day
5, equal number of cells (Total of 1000) was seeded per each well
in 6-well plate and the cell count of each well was measured at day
19 by Coulter Cell Counter Z2 (Beckman Coulter, Inc. Fullerton,
CA). Note that the PD is higher in EGF treated group (2.54 in Ctrl,
3.07 in EGF) for the initial 5 days (∗P<. 05), but this diﬀerence
is reduced in the following 14-day period (10.79 in Ctrl, 11.19 in
EGF)(No signiﬁcant diﬀerence). Shown are representative data of
three independent experiments; each performed in triplicate.4 Journal of Biomedicine and Biotechnology
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Figure 2: Eﬀects of EGF treatment (10nM) on primary human
MSC colony formation. Five hundred cells were seeded in 10cm
dish within culture medium supplemented with 17% FBS and
the number of formed colonies (Diameter ≥1.5mm) was counted
manually in day 14. (a) Representative image of MSC colonies
stained with crystal violet. (b) Colony count of MSC. The number
of colony is given per 1000 cells seeded initially (∗P<. 05 to
EGF treatment). Shown are representative data of two independent
experiments; each performed in triplicate.
2.3. EGF and MSC Diﬀerentiation Potentials. Multidiﬀer-
entiation potential is a key characteristic of MSCs, which
attracts so much attention in the ﬁeld of tissue engineering
and regenerative medicine [4, 5]. Diﬀerentiation potential
itself has to be preserved through the in vitro expansion of
MSCs; however, ongoing diﬀerentiation process itself should
be suppressed or not induced at least as it antagonizes self-
renewal and expansion of undiﬀerentiated MSCs and limits
further use of these cells.
Kratchmarova and her colleagues showed that EGF
stimulation enhances osteogenic diﬀerentiation of human
MSCs in the presence of chemical cues, whereas PDGF does
not [46]. Through mass spectrometry-based proteomics
approach, they identiﬁed PI3K as a molecular switch to turn
oﬀ pro-osteogenic signal from PDGFR.
This report is contradictory to reports by our group
and others. Our data show that EGF alone does not induce
diﬀerentiation in the absence of chemical or other cues,
and does not alter human MSC diﬀerentiation processes
into osteogenic, adipogenic, and chondrogenic lineages by
chemical cues in vitro [3]. This discrepant ﬁnding might be
attributable to a diﬀerent intracellular signaling, as PI3K-
protein kinase B/akt pathway is activated in the downstream
of EGFR/ErbB-1 in our report [3], whereas this pathway is
not activated in their report [46]. The apparent reason for
this discrepancy is unclear, but one prominent diﬀerence
is EGF concentration; 10nM EGF was used in our report
[3], whereas Kratchmarova and her colleagues used 83nM
of EGF in their report [46]. This speculation is supported
by a recent report showing that 80pM EGF inhibits
osteogenic diﬀerentiation of human MSCs [47]. Krampera
andhiscolleaguealsoshowedthatHB-EGF(2.3nM)inhibits
osteogenic diﬀerentiation of MSC induced by chemical cues
[45]. Human MSCs do not express ErbB-4, another receptor
for HB-EGF; both EGF and HB-EGF bind only EGFR/ErbB-
1 on MSC, and downstream signaling cascade is similar
[3, 45].
Do EGFR/ErbB1 agonists exert both positive and neg-
ative eﬀects on osteogenic diﬀerentiation of MSC in a
concentration-dependent manner? And if so, what is the
underlying mechanism? This question is still unresolved, but
we and our collaborators are utilizing immobilized tethered
EGF surface in a manner that provides some important
hints [44, 47]. Tethered EGF blocks EGFR/ErbB1 endo-
cytic internalization and enhances osteogenic diﬀerentiation
through providing sustained activation of downstream sig-
naling through EGFR/ErbB1, whereas 80pM of soluble EGF
interferes with osteogenic diﬀerentiation through inducing
receptor internalization and subsequent degradation [47], in
agreement with Krampera’s data [45]. Thus, we hypothesize
that weak and temporal signaling from low concentration
of soluble EGF exerts anti-osteogenic eﬀects, whereas strong
sustained signaling from tethered EGF exerts pro-osteogenic
signaling on MSC (Figure 3). Previous reports have shown
that the activation of ERK/MAPK pathway, one of the
major signaling pathways in the downstream of EGFR/ErbB-
1[ 3, 42], promotes MSC osteogenic diﬀerentiation [48–
50]. In agreement with these reports, strong and sustained
activation of ERK/MAPK pathway has been observed in
MSCs cultured on tethered EGF surface [44, 47], and
thus, ERK/MAPK pathway might be one of the main
pro-osteogenic signaling pathways in the downstream of
EGFR/ErbB-1.
Other possible reasons for overall discrepancy about
the eﬀects of EGF on MSC diﬀerentiation include the
heterogeneity of human MSC preparations including pri-
mary or immortalized. Kratchmarova and her colleagues
used human MSCs immortalized by human telomerase
reverse transcriptase (hTERT) [46], whereas Krampera and
his colleague used primary human MSCs [45]. We and
Griﬃth’s group also used AOC (Adipogenic, Osteogenic,
Chondrogenic) clone of human MSCs immortalized by
hTERT[3,47,51].AsimmortalizedMSCswerederivedfrom
single clone, it is possible that discrepant results between
Kratchmarova’s group and our group might be due to clone
selection bias. Heterogeneity exists even within primary
preparation too. The expression levels of EGFR/ErbB-1 are
highly variable in each clone of human MSC preparation,
up to 77-fold diﬀerence among clones [52]. In this report,
no signiﬁcant correlation was observed between the lev-
els EGFR/ErbB-1 and osteogenic diﬀerentiation capacity,
although the levels of EGFR/ErbB-1 in average were higher
in nonbone-forming colonies than bone-forming colonies.
Patterns of protein tyrosine phosphorylation downstream of
EGFR/ErbB-1 appeared heterogenous among colonies also.
Thus, it is likely that heterogeneity does exist not only in
EGFR/ErbB-1 expression levels, but also in the downstream
signaling pathways from EGFR/ErbB-1 even within the
same MSC preparation, which should also contribute toJournal of Biomedicine and Biotechnology 5
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Figure 3: Simpliﬁed model for the eﬀects of EGFR/ErbB1 signaling
on MSC osteogenic diﬀerentiation. Weak and temporal stimulation
of EGFR/ErbB1 exerts anti-osteogenic eﬀects, whereas strong and
sustained stimulation of EGFR/ErbB1 exerts pro-osteogenic eﬀects
on MSC.
the overall discrepancy about the eﬀects of EGF on MSC
diﬀerentiation.
As we see above, reports about EGFR agonists and
their eﬀects on ongoing MSC diﬀerentiation still provide
discrepant directives mainly due to diﬀerent EGF conditions
and external stimuli. Still, we need to emphasize that both
our report and Krampera report agree that EGF or HB-EGF
treatment does not diminish MSC diﬀerentiation potentials
[3, 45]. There are no reports showing that EGF alone in
the absence of osteogenic chemical cues promotes osteogenic
diﬀerentiation of MSCs. In vitro MSC diﬀerentiation into
adipogenic and chondrogenic lineages was not altered by
soluble EGF [3]. Thus, soluble EGF can still be used to
expand MSCs in vitro without inducing diﬀerentiation or
sacriﬁcing diﬀerentiation potentials.
3. EGF Treatment to Enhance Therapeutic
Potentials of MSC
3.1. EGF Enhances Motility of MSC. Numerous cellular,
hormonal, matrix and enzymatic activities are involved in
wound repair and tissue regeneration processes. EGF is one
of the pivotal growth factors present in the wound bed,
accelerating wound repair along with other growth factors
such as PDGF. Topical application of recombinant EGF
was shown to accelerate epithelialization of wound healing
process including diabetic foot ulcer [53, 54].
EGF is secreted from platelets and macrophages in
wounded tissues [55]. HB-EGF is abundant in ECM
[56]. Both EGF and HB-EGF stimulate proliferation and
migration of ﬁbroblasts and keratinocytes. Similarly, MSCs
transplanted in the wounded tissues need to proliferate
and repopulate themselves to promote wound healing and
tissue regeneration processes in the MSC-based therapeutics.
We and others showed that both EGF and HB-EGF elicit
mitogenic and motogenic response of MSCs in vitro [3,
45, 52]. Thus, it is speculated that EGF-induced mitogenic
and motogenic responses of MSCs play a role in regulating
proliferation and repopulation of MSCs in the wounded
tissues.
EGFR/ErbB1 ligands exist not only in soluble form, but
also within multiple EGF-like repeats of extracellular matrix
molecules such as tenascin and laminin in vivo [57]. We have
previously shown that these EGF-like repeats within tenascin
C bind to EGFR/ErbB1 and produce intracellular signaling
promoting cell motility and adhesion, similar to tethered
EGF [58, 59]. Tenacin C is produced by keratinocytes
and ﬁbroblasts during wound healing process, and thus it
might serve as endogenous tethered EGF-like ligands and
produce promigratory tracks for ﬁbroblasts or implanted
MSCs within the wound healing edges [57, 60].
Although motility enables MSC to reposition themselves
in wounded tissues, it might make precise control of in
vivo cell distribution diﬃcult. One possible approach is to
create concentration gradients or patterns of tethered EGF
within MSC-embedded scaﬀolds. Motogenic activity of EGF
is preserved in the tethered form, as human keratinocytes
on tethered EGF gradients were reported to migrate in
the direction of higher tethered EGF concentration [61].
Tethered form of EGF allows more precise control of EGF
concentration and patterning within tissue microenviron-
ments and one that lasts over a longer duration. This
connecting of motogenic ligand to the space-forming matrix
should be a strong tool in the ﬁeld of tissue engineering.
3.2. EGF Enhances Paracrine Activities of MSC. MSC-based
therapeutics heavily relies on the strong capability to secrete
various growth factors and cytokines to promote angiogene-
sis, wound repair, and tissue regeneration [7, 21–25]. MSCs
are required to be transplanted into the wounded tissues,
w h i c hf a i lt oh e a lo t h e r w i s e .In vivo microenvironments
of these nonhealing wounds are characterized by lack of
oxygen and nutrients due to compromised blood ﬂow and
by exuberant proinﬂammatory mediators [62–64]. MSCs are
needed to produce bioactive molecules even in those harsh
environments to exert tissue regenerative eﬀects. Indeed,
the proinﬂammatory mediator tumor necrosis factor-alpha
(TNF-α) or lipopolysacharide (LPS) was shown to enhance
paracrine and autocrine functions of MSCs [65]. Also,
TGF-α, another EGFR/ErbB1 ligand, was shown to further
increase VEGF secretion from MSCs already up-regulated by
TNF-α stimulation in a p42/44 MAPK dependent manner
[66, 67].
Our in vitro data showed that EGF treatment of MSCs
further promotes secretion of VEGF and HGF, but not
bFGF (Figure 4), in agreement with a previous study [65].
Both VEGF and HGF play a pivotal role in MSC-mediated
accelerated wound healing through inducing angiogenesis
and improving oxygen supplies to the ischemic tissues [7, 21,
68–70].
Thus, it is likely that soluble EGFR/ErbB1 ligands (TGF-
α, EGF and HB-EGF) enhance paracrine and autocrine
f u n c t i o n so fM S C sn o to n l yin vitro, but also in vivo,
even in the inﬂammatory microenvironments within non-
healing wounded tissues. It is also likely that tethered
EGF enhances paracrine and autocrine functions of MSCs
in vitro as well as in vivo through strong and sustained
activation of p42/44 MAPK pathway in the downstream of
EGFR/ErbB1 [44]. Both soluble and tethered EGFR/ErbB1
ligands are speculated to promote wound healing and
tissueregenerationprocessthroughstimulatingthesecretion
of angiogenic growth factors from transplanted MSCs in
vivo. Further studies are warranted to elucidate the role6 Journal of Biomedicine and Biotechnology
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Figure 4: Eﬀects of EGF treatment (10nM) on paracrine activities of human primary MSCs. MSCs were cultured in serum-free culture
medium with and without EGF (10nM) for 24 hours. Concentrations of VEGF (a), HGF (b), and bFGF (c) within conditioned media were
measured by ELISA and standardized to the total amount of cellular protein contents (∗P<. 05 to EGF treatment). Shown are average data
of three independent experiments; each performed in triplicate.
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Figure 5: Simpliﬁed diagram of EGFR/ErbB1 signaling pathways in MSC physiology. EGFR/ErbB1 ligands activate PLCγ pathway, p42/44
MAPK pathway, and PI3K/Akt pathways in MSCs [3]. PLCγ pathway plays a pivotal role in motogenic activity, whereas p42/44 MAPK
pathway plays a key role in mitogenic activity and paracrine activities of certain factors such as VEGF [42, 43, 66, 67]. Sustained and strong
activation of p42/44 MAPK pathway exerts cytoprotective and pro-osteogenic eﬀects [44, 47], whereas PI3K/Akt pathway might exert anti-
osteogenic eﬀects [46].
of soluble EGFR/ErbB1 ligands and tethered EGF on the
paracrine and autocrine eﬀects of MSCs in vitro as well as
in vivo.
3.3. Does EGF Enhance Therapeutic Potentials of MSC? EGF
stimulates cell proliferation and enhances self-renewal of
MSCs, especially undiﬀerentiated early progenitors within
the MSC preparations in vitro. The presence of early
progenitors is critical for MSC-based therapeutics, as MSCs
from old donors and high passaged MSCs have decreased
paracrine activity and reduced organ protective eﬀects upon
transplantation, presumably through loss of early progen-
itors [27, 29, 30, 36, 39]. EGF treatment also enhances
cell motility, which is required for repopulation of MSCs
within the wound bed. EGF treatment further increases
paracrine secretion of VEGF and HGF, both of which
enhance angiogenesis and promote wound healing and
tissue regeneration also being stimulatory for the adherent
cells resident within the wound bed. Taken together, it
is reasonable to hypothesize that in vitro MSC treatment
with EGFR/ErbB1 ligands enhances therapeutic potentials of
MSCs. This could be tested by in vivo study.Journal of Biomedicine and Biotechnology 7
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Figure 6: The roles of soluble and tethered EGFR/ErbB1 ligands
on MSC physiology. Soluble EGFR/ErbB1 ligands (EGF, HB-EGF,
TGF-α) enhance paracrine secretions, proliferation, and migration
of MSCs. Tethered EGF or EGF-like repeats within tenascin or
laminin augment osteogenic diﬀerentiation of MSCs, in addition
to cytoprotective, motogenic, and mitogenic eﬀects on MSCs.
It is also reasonable to hypothesize that EGFR/ErbB1
stimulation on MSC enhances therapeutic potentials of
MSCs in vivo, presumably through augmenting paracrine
activityandexertingbothmitogenicandmotogenicactivities
of MSCs. Biodegradable scaﬀolds are a promising approach
to support cell delivery, guide proliferation and diﬀerenti-
ation of the cells [71]. Drug delivery scaﬀolds or growth
factor release scaﬀolds are also available, which enables the
controlled release of growth factor [72]. Availability of EGF
islesspredictableinvivosetting;however,EGFslowreleasing
scaﬀolds allow for better prediction of EGF concentration
within microenvironments in vivo, thus, in vitro ﬁndings
should be better translated to the in vivo settings and the role
of EGF in MSC-based therapeutics could be better evaluated.
InadditiontosolubleEGFR/ErbB1ligands,tetheredEGF
might bestow even stronger therapeutic potential on MSCs.
First, tethered EGF exerts proliferative and cytoprotective
eﬀects on MSCs [44, 73]. Therapeutic eﬀects of MSC largely
depend on the number of injected MSC [19]; however, low
viability of postimplant MSCs limits the overall eﬀectiveness
of MSC-based therapeutics due to harsh microenvironments
[15, 74]. Thus, improvement of postimplant MSC survival
should increase the eﬃcacy of MSC-based therapeutics.
Second, tethered EGF provides pro-osteogenic cues for
MSCs, thus it could be utilized in both in vitro and in
vivo osteogenic diﬀerentiation of MSCs. This mechanism
might play a signiﬁcant role in vivo, as laminin 5, which
containsEGF-likerepeats,wasshowntostimulateosteogenic
diﬀerentiation of human MSCs through activation of ERK
within bone tissue [75]. Thus, MSC-embedded scaﬀold with
tethered EGF could be potentially applicable to current
human studies such as osteogenic imperfecta [76–78].
The challenge of translating theoretical ﬁndings to
bedsides always resides in moving from in vitro to in vivo
studies and then into people. While we cannot foresee
all the obstacles, the main challenge in this translation
involves the inﬂammatory situation and immunological
issues. In the case of the latter, this is moot if the MSCs
are autologous, but allogenic MSCs are also useful, especially
for aged patients, as MSC harvest and subsequent ex vivo
expansion might be limited for those populations [26, 39].
The immunosuppressive nature of MSC makes allogenic
transplantation feasible [26]. Nonspeciﬁc inﬂammation due
to any foreign body is something not avoidable. Actually
we propose that the tethered EGF confer resistance to
death signals on MSCs [44]. Still the complex mixture
of inﬂammatory cytokines and chemokines may alter the
response to EGFR/ErbB1 ligands in unpredictable ways.
Lastly, if the inﬂammatory response runs towards ﬁbro-
sis, MSCs risk being walled-oﬀ from the site of injury.
Another potential challenge of the translation into people
is underlying disease conditions, as nutrient delivery, oxygen
supplies, and removal of toxic metabolites are often severely
compromised in these populations [62–64]; in diabetes the
hyperglycemia also impacts EGFR signaling pathways [79,
80]. These harsh microenvironments, with alter extracellular
pH, will impinge on the MSC behavior in an unpredictable
manner. That is why we are quickly moving to test these
models in increasingly challenged animal models.
4.Epilogue
Previous studies suggest that EGF facilitates expansion of
colony forming early progenitors in MSC population with-
outinducingdiﬀerentiationorcompromisingdiﬀerentiation
potentials. EGF treatment also promotes paracrine activity
of MSC, at least the production of VEGF and HGF, both of
which are pivotal for wound healing and tissue regeneration.
EGF can be utilized to promote expansion and paracrine
activities of MSCs in vitro, at least with short-term treatment
with EGF. For in vivo settings, EGF can be incorporated
in growth factor-releasing scaﬀolds encapsulating MSCs to
augment MSC proliferation and paracrine action. Tethered
form of EGF can also be incorporated in the scaﬀold
to control osteogenic diﬀerentiation of MSCs or MSC
distributions in vivo. The roles of EGFR/ErbB1 ligands
and downstream signaling from EGFR/ErbB1 on MSC
physiology are summarized in Figures 5 and 6.O v e r a l l ,i t
should be reasonable to utilize EGF for MSC expansion in
vitro, enhancement of MSC therapeutic potentials in vivo,
and regulation of MSC diﬀerentiation both in vitro and in
vivo.
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